Regeneron Pharmaceuticals Inc.

12/17/2024 | Press release | Distributed by Public on 12/17/2024 06:00

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following[...]